

Ref: FOI/GS/ID 9416

Please reply to:
FOI Administrator
Trust Management
Maidstone Hospital
Hermitage Lane
Maidstone, Kent
ME16 9QQ
Email: mtw-tr.foiadmin@nhs.net
www.mtw.nhs.uk

25 October 2024

Freedom of Information Act 2000

I am writing in response to your request for information made under the Freedom of Information Act 2000 in relation to chronic lymphocytic leukaemia.

*You asked: All questions are shown as received by the Trust.
Please answer the questions with regards to NHS patients, i.e., excluding patients that received treatment as part of clinical trials or private healthcare.*

1. *How many newly diagnosed patients with chronic lymphocytic leukaemia (CLL) have started first-line treatment in your Trust or Centre during the 6-month period February 2024 to July 2024?*
2. *How many of these newly diagnosed patients with CLL received chemoimmunotherapy (CIT) as first-line treatment?
CITs include fludarabine + cyclophosphamide + rituximab (FCR), fludarabine + rituximab (FR), bendamustine + rituximab (BR), bendamustine monotherapy, rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone (R-CHOP), obinutuzumab ± chlorambucil, rituximab + chlorambucil and ofatumumab*
3. *Please complete the table below with how many newly diagnosed patients with CLL have started first-line treatment with each of the following CITs during the 6-month period February 2024 to July 2024*
 - a. *FCR (fludarabine + cyclophosphamide + rituximab)*
 - b. *FR (fludarabine + rituximab)*
 - c. *BR (bendamustine + rituximab)*
 - d. *Bendamustine monotherapy*
 - e. *RCHOP (Rituximab + cyclophosphamide + doxorubicin + vincristine + prednisolone)*
 - f. *Obinutuzumab ± chlorambucil*
 - g. *Rituximab + chlorambucil*
 - h. *Ofatumumab*
 - i. *Other – please specify*

Note: this should only include newly diagnosed patients with CLL who have started first-line treatment during the 6-month window

Trust response:

1. 7

2. 7

3.

f. Venetoclax and Obinutuzumab 1

g. Rituximab 1

i. Acalabrutinib 4

Zanubrutinib 1